Exact Sciences Corporation

Equities

EXAS

US30063P1057

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-21 EDT			5-day change	1st Jan Change
44.85 ^USD	+1.93%		+7.09%	-39.38%

06-11	Exact Sciences Seeks Acquisitions	CI
06-11	Transcript : Exact Sciences Corporation Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 03:20 PM

Exact Sciences Corporation Announces Resignation of Everett Cunningham, Chief Commercial Officer, Effective on June 13, 2024

June 03, 2024 at 07:01 am

Exact Sciences Corporation reported that on May 30, 2024, Everett Cunningham, Chief Commercial Officer, informed the Company that effective on June 13, 2024 he will be departing for an opportunity with an organization that does not compete with the Company.

Latest news about Exact Sciences Corporation

Exact Sciences Seeks Acquisitions	06-11	CI
Transcript : Exact Sciences Corporation Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 03:20 PM	06-11
Biocartis NV Appoints Gina Wallar as Chief Business Officer	06-10	CI
Transcript : Exact Sciences Corporation Presents at Jefferies 2024 Global Healthcare Conference, Jun-05-2024 11:00 AM	06-05
Transcript : Exact Sciences Corporation Presents at The 44th Annual William Blair Growth Stock Conference, Jun-04-2024 12:40 PM	06-04
Exact Sciences Corporation Reaffirms Earnings Guidance for the Second-Quarter 2024 and Full-Year 2024	06-03	CI
Exact Sciences Corporation Announces Resignation of Everett Cunningham, Chief Commercial Officer, Effective on June 13, 2024	06-03	CI
Sector Update: Health Care Stocks Advance Pre-Bell Friday	05-24	MT
Exact Sciences to Present New Data at Oncology Annual Meeting Confirming Prognostic Value of Breast Cancer Test	05-24	MT
Exact Sciences Demonstrates Continued Leadership in Early Cancer Diagnosis and Improved Health Outcomes for Patients with Multiple Data Presentations At Asco®	05-24	CI
U.S. FDA advisers back approval for Guardant's cancer test	05-23	RE
Exact Sciences Says Court Allows Patent Lawsuit Against Geneoscopy to Proceed	05-21	MT
Transcript : Exact Sciences Corporation Presents at Bank of America Health Care Conference 2024, May-15-2024 01:40 PM	05-15
Exact Sciences Q1 Net Loss Widens, Revenue Increases; 2024 Revenue Outlook Maintained -- Shares Fall After Hours	05-08	MT
Transcript : Exact Sciences Corporation, Q1 2024 Earnings Call, May 08, 2024	05-08
Earnings Flash (EXAS) EXACT SCIENCES Reports Q1 Revenue $637.5M, vs. Street Est of $626.8M	05-08	MT
Exact Sciences Corporation Reports Unaudited Consolidated Impairment of Long-Lived Assets for the First Quarter Ended March 31, 2024	05-08	CI
Exact Sciences Corporation Maintains Revenue Guidance for the Full Year of 2024	05-08	CI
Exact Sciences Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
Exact Sciences Corporation Announces Board Resignations	04-25	CI
Exact Sciences Corporation announced that it has received $266.75 million in funding	04-16	CI
Sector Update: Health Care Stocks Advance Premarket Monday	04-15	MT
Exact Sciences Names Aaron Bloomer CFO	04-15	MT
Exact Sciences Appoints Aaron Bloomer as Chief Financial Officer, Effective from May 15, 2024	04-15	CI
Exact Sciences Corporation Announces Executive Changes	04-15	CI

Chart Exact Sciences Corporation

Duration

Period

More charts

Company Profile

Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The Company is focusing its research and development efforts on three main areas: Colorectal Cancer Screening, MCED Test Development and MRD Test Development. The Companyâs products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, and OncoExTra Test. The Companyâs flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patientâs breast tumor tissue.

Sector

Biotechnology & Medical Research

Calendar

2024-07-29 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Exact Sciences Corporation

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

44.85 USD

Average target price

84.86 USD

Spread / Average Target

+89.21%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Diagnostics & Testing

	1st Jan change	Capi.
EXACT SCIENCES CORPORATION	-39.38%	8.28B
GUARDANT HEALTH, INC.	+9.28%	3.62B
IOVANCE BIOTHERAPEUTICS, INC.	-1.48%	2.24B
BGI GENOMICS CO., LTD.	-22.85%	1.94B
VERACYTE, INC.	-18.07%	1.72B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+10.53%	962M
CAREDX, INC	+17.17%	734M
SEEGENE, INC.	-9.17%	690M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-33.88%	477M
CURIOX BIOSYSTEMS CO., LTD	+2.58%	298M

Bio Diagnostics & Testing